The BalancedInvestor Club

IMDX Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-1.650.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$134.5MMicro cap

Wall Street coverage

$8.33median target· current $2.77 (+200.7%)4 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
—
PEG ratio
—
P/B
196.27
P/S (TTM)
33.16
EV/EBITDA
-1.25

Profitability & growth

ROE (TTM)
-23603.0%
Operating margin
-874.0%
Revenue growth YoY
-23.4%
Dividend yield
—
Beta
1.53
Last earnings
Mar 27, 2026 · Estimate $-0.24 · Reported $-0.72
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Insight Molecular Diagnostics Inc.

OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.

Classification

Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
2 INTERNATIONAL PLAZA DR., NASHVILLE, TN
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$134.5M
Shares outstanding$32.2M
52W high$8.51
52W low$2.33

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer